Metoject Pen (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, halting the formation of tetrahydrofolate needed for DNA and RNA synthesis. This limits the proliferation of rapidly dividing cells, including activated immune cells and cancer cells, and also raises extracellular adenosine levels, providing anti‑inflammatory effects.

The dose of Metoject Pen is individualized by the prescribing clinician based on the specific indication, disease severity, patient weight, renal and hepatic function, and response to therapy. No standard dosing can be provided without a medical assessment.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also excreted in breast milk, so breastfeeding is not recommended while using this medication.

To request Metoject Pen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Metoject Pen offers a convenient pre‑filled subcutaneous delivery system, which can improve patient adherence compared with oral tablets that may have variable absorption. Compared with other injectable forms, the pen provides precise dosing and reduces injection‑site discomfort. Alternative disease‑modifying agents, such as biologic DMARDs, have different mechanisms and safety profiles, so choice depends on clinical response and physician judgment.

Metoject Pen should be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the pen in its original packaging, protect it from light, and avoid freezing or shaking. If a short period outside the refrigerator is unavoidable, follow the manufacturer’s guidance on temperature excursions.

Metoject Pen is a pre‑filled, single‑use device designed for subcutaneous injection. After confirming the prescribed dose, the pen is placed against the skin (typically on the abdomen or thigh), the needle is activated, and the medication is delivered by pressing the plunger. Patients should be trained by a healthcare professional on proper technique and disposal.

The most serious adverse events include severe liver toxicity, pulmonary fibrosis or interstitial pneumonitis, profound bone‑marrow suppression leading to anemia, leukopenia or thrombocytopenia, and acute kidney injury. Early detection through regular laboratory monitoring is essential to mitigate these risks.

Metoject Pen is contraindicated in pregnant women, individuals planning pregnancy without effective contraception, and patients with severe hepatic or renal impairment. It should also be avoided in patients with known hypersensitivity to methotrexate or any component of the pen, and in those receiving live vaccines due to heightened infection risk.